Ptc Therapeutics annual ebitda margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ptc Therapeutics EBITDA Margin Growth & History (PTCT)
Ptc Therapeutics's ebitda margin was 52.34% for fiscal 2025.
View full Ptc Therapeutics company overviewPtc Therapeutics annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 52.34% | +80.46 pp |
| 2024 | 2024-12-31 | −28.13% | −6.49 pp |
| 2023 | 2023-12-31 | −21.64% | +23.95 pp |
| 2022 | 2022-12-31 | −45.59% | +12.03 pp |
| 2021 | 2021-12-31 | −57.61% | +44.36 pp |
| 2020 | 2020-12-31 | −101.97% | −33.90 pp |
| 2019 | 2019-12-31 | −68.08% | −34.23 pp |
| 2018 | 2018-12-31 | −33.84% | −9.87 pp |
| 2017 | 2017-12-31 | −23.98% | +131.72 pp |
| 2016 | 2016-12-31 | −155.70% | +291.06 pp |
| 2015 | 2015-12-31 | −446.76% | −61.82 pp |
| 2014 | 2014-12-31 | −384.94% | −261.00 pp |
| 2013 | 2013-12-31 | −123.94% | −52.93 pp |
| 2012 | 2012-12-31 | −71.01% | −102.74 pp |
| 2011 | 2011-12-31 | 31.74% | — |
Ptc Therapeutics quarterly ebitda margin
Q3.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 45.73% | +61.03 pp |
| Q1 2026 | 2026-03-31 | 22.15% | −60.96 pp |
| Q4 2025 | 2025-12-31 | −35.49% | +37.51 pp |
| Q3 2025 | 2025-09-30 | 6.69% | +31.10 pp |
| Q2 2025 | 2025-06-30 | −15.30% | +2.48 pp |
| Q1 2025 | 2025-03-31 | 83.11% | +78.38 pp |
| Q4 2024 | 2024-12-31 | −73.00% | −101.18 pp |
| Q3 2024 | 2024-09-30 | −24.40% | +4.14 pp |
| Q2 2024 | 2024-06-30 | −17.78% | +56.37 pp |
| Q1 2024 | 2024-03-31 | 4.73% | +38.67 pp |
| Q4 2023 | 2023-12-31 | 28.18% | +124.63 pp |
| Q3 2023 | 2023-09-30 | −28.54% | −13.02 pp |
| Q2 2023 | 2023-06-30 | −74.15% | −35.98 pp |
| Q1 2023 | 2023-03-31 | −33.94% | +6.54 pp |
| Q4 2022 | 2022-12-31 | −96.45% | −56.56 pp |
| Q3 2022 | 2022-09-30 | −15.53% | +39.49 pp |
| Q2 2022 | 2022-06-30 | −38.17% | +33.40 pp |
| Q1 2022 | 2022-03-31 | −40.48% | +31.22 pp |
| Q4 2021 | 2021-12-31 | −39.89% | +30.75 pp |
| Q3 2021 | 2021-09-30 | −55.01% | −18.28 pp |
| Q2 2021 | 2021-06-30 | −71.57% | +163.76 pp |
| Q1 2021 | 2021-03-31 | −71.70% | +51.01 pp |
| Q4 2020 | 2020-12-31 | −70.64% | +15.59 pp |
| Q3 2020 | 2020-09-30 | −36.73% | +26.71 pp |
| Q2 2020 | 2020-06-30 | −235.33% | −206.71 pp |
| Q1 2020 | 2020-03-31 | −122.70% | −18.19 pp |
| Q4 2019 | 2019-12-31 | −86.24% | −21.95 pp |
| Q3 2019 | 2019-09-30 | −63.44% | +2.55 pp |
| Q2 2019 | 2019-06-30 | −28.63% | −37.70 pp |
| Q1 2019 | 2019-03-31 | −104.52% | −95.08 pp |
| Q4 2018 | 2018-12-31 | −64.29% | −67.18 pp |
| Q3 2018 | 2018-09-30 | −65.99% | −39.95 pp |
| Q2 2018 | 2018-06-30 | 9.08% | +33.43 pp |
| Q1 2018 | 2018-03-31 | −9.44% | +87.92 pp |
| Q4 2017 | 2017-12-31 | 2.89% | +99.15 pp |
| Q3 2017 | 2017-09-30 | −26.04% | +109.91 pp |
| Q2 2017 | 2017-06-30 | −24.35% | +204.30 pp |
| Q1 2017 | 2017-03-31 | −97.36% | +101.60 pp |
| Q4 2016 | 2016-12-31 | −96.26% | +276.01 pp |
| Q3 2016 | 2016-09-30 | −135.96% | +288.27 pp |
| Q2 2016 | 2016-06-30 | −228.65% | +331.45 pp |
| Q1 2016 | 2016-03-31 | −198.96% | +301.40 pp |
| Q4 2015 | 2015-12-31 | −372.26% | −121.90 pp |
| Q3 2015 | 2015-09-30 | −424.22% | +1173.06 pp |
| Q2 2015 | 2015-06-30 | −560.10% | +919.15 pp |
| Q1 2015 | 2015-03-31 | −500.36% | −352.55 pp |
| Q4 2014 | 2014-12-31 | −250.37% | +146.56 pp |
| Q3 2014 | 2014-09-30 | −1,597.28% | −1574.65 pp |
| Q2 2014 | 2014-06-30 | −1,479.25% | −1277.09 pp |
| Q1 2014 | 2014-03-31 | −147.81% | −36.49 pp |
| Q4 2013 | 2013-12-31 | −396.93% | — |
| Q3 2013 | 2013-09-30 | −22.63% | +66.15 pp |
| Q2 2013 | 2013-06-30 | −202.16% | — |
| Q1 2013 | 2013-03-31 | −111.33% | — |
| Q3 2012 | 2012-09-30 | −88.78% | — |
Ptc Therapeutics ebitda margin trends
Over the last five fiscal years, Ptc Therapeutics's ebitda margin increased from −101.97% to 52.34%, a change of +154.31 percentage points. The latest reported quarter, Q2 2026, shows 45.73%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ptc Therapeutics source filings ↗Community posts
PTC raises its revenue forecast as Sephience sales expand
PTC Therapeutics ($PTCT) raised its full-year 2026 revenue expectation to $1.29–$1.32 billion and increased product-sales guidance to $960–$990 million from $850–$950 million. Third-quarter 2026 product and royalty revenue reached $357.6 mi ...
